While early trials of TCR-engineered T cells (e.g., MART-1 TCR, tyrosinase TCR, etc.)have shown various degrees of efficacy in inducing tumor regression in patients with metastatic melanoma, further improvements to TCR constructs or modifications to the treatment protocols are needed to increase the efficacy of TCR-engineered T cells in the treatment of melanoma. The gene discussed is TYR; the disease is neoplasm.